Management of Immune Checkpoint Inhibitor Toxicities

Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherap...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Manag Res
Auteurs principaux: Durrechou, Quentin, Domblides, Charlotte, Sionneau, Baptiste, Lefort, Felix, Quivy, Amandine, Ravaud, Alain, Gross-Goupil, Marine, Daste, Amaury
Format: Artigo
Langue:Inglês
Publié: Dove 2020
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7533913/
https://ncbi.nlm.nih.gov/pubmed/33061607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S218756
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires